HRP20130229T1 - Primjena cjepiva bez igle za felv - Google Patents

Primjena cjepiva bez igle za felv Download PDF

Info

Publication number
HRP20130229T1
HRP20130229T1 HRP20130229TT HRP20130229T HRP20130229T1 HR P20130229 T1 HRP20130229 T1 HR P20130229T1 HR P20130229T T HRP20130229T T HR P20130229TT HR P20130229 T HRP20130229 T HR P20130229T HR P20130229 T1 HRP20130229 T1 HR P20130229T1
Authority
HR
Croatia
Prior art keywords
vaccine
felv
viral vector
vector
used according
Prior art date
Application number
HRP20130229TT
Other languages
English (en)
Inventor
Tesfai Tseggai
Maria Camila Pardo
Alton Timothy Leard
Original Assignee
Merial Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Limited filed Critical Merial Limited
Publication of HRP20130229T1 publication Critical patent/HRP20130229T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2250/00—Specially adapted for animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

1. Cjepivo, naznačeno time, da sadrži učinkovitu količinu rekombinantnog virusnog vektora koji kodira i vrši ekspresiju za najmanje jedan FeLV imunogen te prihvatljiv nosač ili razrjeđivač, te da se upotrebljava za izazivanje pouzdanog i zaštitničkog imunološkog odgovora protiv FeLV, putem primjene na životinjama iz porodice felida, pomoću injektora bez igle koji ima mlaznice s tekućinom.
2. Cjepivo prema zahtjevu 1, naznačen time, da se upotrebljava prema zahtjevu 1, pri čemu virusni vektor je vektor virusa herpesa, vektor adenovirusa ili vektor poksvirusa.
3. Cjepivo prema zahtjevu 2, naznačen time, da se upotrebljava prema zahtjevu 2, pri čemu virusni vektor je kanarinski poksvirus ili poksvirus peradi.
4. Cjepivo prema zahtjevu 2, naznačen time, da se upotrebljava prema zahtjevu 2, pri čemu virusni vektor je vCP97.
5. Cjepivo prema bilo kojem od zahtjeva 1 do 4, naznačen time, da se upotrebljava prema zahtjevima 1 do 4, pri čemu cjepivo obuhvaća od oko 104,5 do oko 107,0TCID50/doza (virusna doza koja je 50% inficirane kulture tkiva prema dozi cjepiva).
6. Cjepivo prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se upotrebljava prema zahtjevima 1 do 5, pri čemu je injektor bez igle koji ima mlaznice s tekućinom - uređaj VitajetTM.
7. Pribor ili garnitura cjepiva, naznačen(a) time, da obuhvaća injektor bez igle koji ima mlaznice s tekućinom i najmanje jednu fijalu s cjepivom, koja sadrži rekombinantno cjepivo za FeLV na bazi virusnog vektora, a sklopljen(a) je funkcionalno za izvršenje primjene cjepiva na životinji iz porodice felida i za izazivanje pouzdanog i zaštitničkog imunološkog odgovora protiv FeLV.
8. Uporaba učinkovite količine rekombinantnog virusnog vektora koji kodira i vrši ekspresiju za najmanje jedan FeLV imunogen te prihvatljiv nosač ili razrjeđivač, naznačena time, da je za proizvodnju cjepiva koje izaziva pouzdan i zaštitnički imunološki odogovor protiv FeLV, putem primjene na životinje iz porodice felida pomoću injektora bez igle koji ima mlaznice s tekućinom.
HRP20130229TT 2004-06-04 2013-03-15 Primjena cjepiva bez igle za felv HRP20130229T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57677104P 2004-06-04 2004-06-04
PCT/US2005/019816 WO2005117959A2 (en) 2004-06-04 2005-06-06 NEEDLE-FREE ADMINISTRATION OF FeLV BVACCINES

Publications (1)

Publication Number Publication Date
HRP20130229T1 true HRP20130229T1 (hr) 2013-04-30

Family

ID=35463354

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130229TT HRP20130229T1 (hr) 2004-06-04 2013-03-15 Primjena cjepiva bez igle za felv

Country Status (9)

Country Link
US (1) US7582302B2 (hr)
EP (1) EP1765387B1 (hr)
CN (1) CN1997389B (hr)
CA (1) CA2570156C (hr)
DK (1) DK1765387T3 (hr)
HR (1) HRP20130229T1 (hr)
RS (1) RS52705B (hr)
SI (1) SI1765387T1 (hr)
WO (1) WO2005117959A2 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7455844B2 (en) 2006-03-29 2008-11-25 Merial Limited Vaccine against streptococci
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
ES2760004T3 (es) 2008-05-08 2020-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacuna contra Leishmania utilizando un inmunnógeno salival de mosca de la arena
CL2009001564A1 (es) * 2008-07-11 2010-09-24 Intervet Int Bv Vacuna contra el virus de la leucemia felina (felv) que comprende un adenovirus que contiene un gen del felv; adenovirus recombinante que comprende un adn del adenovirus del felv.
MX351642B (es) 2011-07-20 2017-10-23 Merial Ltd Vacuna para virus de leucemia felina recombinante que contiene gen de envoltura del virus de leucemia felina optimizado.
WO2013123242A1 (en) 2012-02-14 2013-08-22 Merial Limited Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
AU2013235423B2 (en) 2012-03-20 2017-03-30 Boehringer Ingelheim Animal Health USA Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof
WO2015085242A1 (en) 2013-12-05 2015-06-11 Merial Limited Skin innate response linked to protective intradermal vaccination against respiratory infection
CN105999257A (zh) * 2016-05-11 2016-10-12 长春海基亚生物技术股份有限公司 无针注射流感疫苗系统与应用
CN105999259A (zh) * 2016-05-11 2016-10-12 长春海基亚生物技术股份有限公司 无针注射狂犬病疫苗系统与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374424A (en) * 1986-10-03 1994-12-20 Miles Inc. Multivalent felv-infected feline vaccine
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
FR2751228B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
AU7064700A (en) * 1999-08-20 2001-03-19 Bioject, Inc. Intramuscular injection system for injecting dna-based injectables into humans

Also Published As

Publication number Publication date
EP1765387A4 (en) 2007-07-04
CN1997389B (zh) 2010-06-16
RS52705B (en) 2013-08-30
US7582302B2 (en) 2009-09-01
EP1765387B1 (en) 2013-01-09
SI1765387T1 (sl) 2013-04-30
CA2570156C (en) 2014-09-30
CA2570156A1 (en) 2005-12-15
CN1997389A (zh) 2007-07-11
WO2005117959A2 (en) 2005-12-15
WO2005117959A3 (en) 2006-05-04
DK1765387T3 (da) 2013-03-04
US20060034867A1 (en) 2006-02-16
EP1765387A2 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
HRP20130229T1 (hr) Primjena cjepiva bez igle za felv
Subbarao et al. Development of effective vaccines against pandemic influenza
Voigt et al. Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2)
ES2645156T3 (es) Agente terapéutico inmunológico de acción rápida y prolongada
Lambe Novel viral vectored vaccines for the prevention of influenza
Dong et al. Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice
Starodubova et al. Rabies vaccines: Current status and prospects for development
Marín-López et al. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR (−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus
Kumar et al. Plant-derived immuno-adjuvants in vaccines formulation: a promising avenue for improving vaccines efficacy against SARS-CoV-2 virus
DiStefano et al. Immunogenicity of a reduced-dose whole killed rabies vaccine is significantly enhanced by ISCOMATRIX™ adjuvant, Merck amorphous aluminum hydroxylphosphate sulfate (MAA) or a synthetic TLR9 agonist in rhesus macaques
Patial et al. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2
Lodmell et al. Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody
Imoto et al. Needle-free jet injection of small doses of Japanese encephalitis DNA and inactivated vaccine mixture induces neutralizing antibodies in miniature pigs and protects against fetal death and mummification in pregnant sows
Liang et al. Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from Bovine viral diarrhea virus in cattle
Konishi et al. Simultaneous immunization with DNA and protein vaccines against Japanese encephalitis or dengue synergistically increases their own abilities to induce neutralizing antibody in mice
Zinkernagel Immunity, immunopathology and vaccines against HIV?
Almeida et al. Indirect oral immunization of captive vampires, Desmodus rotundus
Stachyra et al. Highly immunogenic prime–boost DNA vaccination protects chickens against challenge with homologous and heterologous H5N1 virus
Silveira et al. Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice
Kumar et al. Recent advances in vaccine development for the treatment of emerging infectious diseases
Ryan et al. The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-γ by Natural Killer (NK) cells enhancing Th1 polarization
Zhao et al. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice
Choudhury et al. Recent development of ruminant vaccine against viral diseases
Röhrs et al. A model for early onset of protection against lethal challenge with highly pathogenic H5N1 influenza virus
Morein Potentiation of the immune response by immunization with antigens in defined multimeric physical forms